Dashboard
Manage Tickers

DCPH


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

deciphera-pharmaceuticals-cash-position-as-of-december-31-2023-were-3529m-which-is-expected-to-provide-cash-runway-into-second-half-of-2026
Deciphera Pharmaceuticals' Cash Position A...
02/06/2024 12:03:05

deciphera-pharmaceuticals-q4-eps-054-beats-058-estimate-sales-4830m-beat-4592m-estimate
Deciphera Pharmaceuticals Q4 EPS $(0.54) B...
02/06/2024 12:01:33

Deciphera Pharmaceuticals (NASDAQ:DCPH) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimat...

earnings-scheduled-for-february-6-2024
Earnings Scheduled For February 6, 2024
02/06/2024 10:42:06

Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of ...

earnings-outlook-for-deciphera-pharmaceuticals
Earnings Outlook For Deciphera Pharmaceuti...
02/05/2024 19:02:18

deciphera-pharmaceuticals-results-of-intrigue-study-long-term-follow-up-in-the-primary-analysis-of-the-ap-itt-population-based-on-a-data-cut-of-september-1-2021-the-primary-endpoint-was-not-achieved
Deciphera Pharmaceuticals Results Of INTRI...
01/18/2024 16:17:52

Results of INTRIGUE Study Long-Term Follow-UpIn INTRIGUE, 453 patients in the all-patient intent-to-treat population (AP-ITT) w...

deciphera-pharmaceuticals-presents-long-term-follow-up-results-from-intrigue-phase-3-clinical-study-in-second-line-gist-patients-at-the-2024-american-society-of-clinical-oncology-gastrointestinal-cancers-symposium
Deciphera Pharmaceuticals Presents Long-Te...
01/18/2024 16:14:46

– Median Overall Survival for QINLOCK® of 35.5 Months Versus 31.5 Months for Sunitinib in the All-Patient Intent-to Treat-Popul...

genesis-pharma-and-deciphera-pharmaceuticals-have-announced-an-exclusive-distribution-agreement-for-ripretinib-in-14-european-markets-in-central-and-eastern-europe-for-the-commercialization-of-ripretinib-for-fourth-line-gastrointestinal-stromal-tumor
Genesis Pharma And Deciphera Pharmaceutica...
01/12/2024 11:39:41

deciphera-pharmaceuticals-preliminary-unaudited-cash-cash-equivalents-and-marketable-securities-of-approximately-352m-as-of-december-31-2023-cash-runway-extended-into-the-second-half-of-2026
Deciphera Pharmaceuticals Preliminary Unau...
01/08/2024 12:17:51

deciphera-pharmaceuticals-preliminary-unaudited-q4-2023-qinlock-net-product-revenue-of-approximately-46m-up-40-yy
Deciphera Pharmaceuticals' Preliminary Una...
01/08/2024 12:17:08

Expects to Submit Vimseltinib New Drug Application (NDA) in the Second Quarter of 2024 and Marketing Authorisation Applicatio...

deciphera-pharmaceuticals-announces-nature-medicine-publication-of-results-from-exploratory-ctdna-analysis-from-intrigue-phase-3-study-demonstrating-substantial-clinical-benefit-of-qinlock-in-2l-gist-patients-with-mutations-in-kit-exon-11-and-1718
Deciphera Pharmaceuticals Announces Nature...
01/05/2024 12:02:10

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializ...

what-4-analyst-ratings-have-to-say-about-deciphera-pharmaceuticals
What 4 Analyst Ratings Have To Say About D...
11/20/2023 19:00:35

jp-morgan-reinstates-neutral-on-deciphera-pharmaceuticals-announces-14-price-target
JP Morgan Reinstates Neutral on Deciphera ...
11/20/2023 13:17:17

JP Morgan analyst Jessica Fye reinstates Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Neutral and announces $14 price target.

stifel-maintains-buy-on-deciphera-pharmaceuticals-raises-price-target-to-22
Stifel Maintains Buy on Deciphera Pharmace...
10/31/2023 18:00:34

Stifel analyst Bradley Canino maintains Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Buy and raises the price target from ...

hc-wainwright--co-maintains-buy-on-deciphera-pharmaceuticals-raises-price-target-to-30
HC Wainwright & Co. Maintains Buy on Decip...
10/31/2023 11:36:49

HC Wainwright & Co. analyst Andrew Fein maintains Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Buy and raises the pric...

jonestrading-upgrades-deciphera-pharmaceuticals-to-buy
JonesTrading Upgrades Deciphera Pharmaceut...
10/31/2023 09:52:03

JonesTrading analyst Soumit Roy upgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Hold to Buy.

piper-sandler-upgrades-deciphera-pharmaceuticals-to-overweight-raises-price-target-to-23
Piper Sandler Upgrades Deciphera Pharmaceu...
10/30/2023 16:58:26

Piper Sandler analyst Christopher Raymond upgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Neutral to Overweight and ra...

deciphera-pharmaceuticals-investigational-drug-shows-encouraging-response-rates-in-rare-type-of-cancer
Deciphera Pharmaceuticals' Investigational...
10/30/2023 15:22:10

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) announced top-line results from the MOTION Phase 3 study of vimseltinib in patient...

western-digital-jinkosolar-lumentum-holdings-and-other-big-stocks-moving-higher-on-monday
Western Digital, JinkoSolar, Lumentum Hold...
10/30/2023 14:19:29

U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording...

Core News & Articles
Market-Moving News for October 30th
10/30/2023 12:50:10

DCPH: 38% | Deciphera Pharma shares are trading higher after the company announced its study of patients with TGCT met its prim...

deciphera-pharmaceuticals-shares-resumed-at-73000-am-et-up-35-following-primary-and-secondary-endpoints-met-in-tgct-trial
Deciphera Pharmaceuticals Shares Resumed a...
10/30/2023 11:34:23

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION